Pharmaceutical Corporate Manslaughter and Criminal Accountability:

Abstract

The pharmaceutical industry occupies a unique position within modern regulatory states, operating at the intersection of profit-driven corporate enterprise and public health imperatives. Recent public health catastrophes, most notably the opioid epidemic in the United States and recurrent incidents involving contaminated pharmaceutical products, have reignited debate regarding the scope and adequacy of corporate criminal liability. This paper examines whether drug manufacturers can, and should, be held criminally liable for large-scale loss of life under doctrines analogous to corporate manslaughter, and whether piercing the corporate veil offers a viable pathway to individual accountability. Through doctrinal analysis of corporate criminal liability, statutory frameworks governing pharmaceuticals, and comparative perspectives on corporate manslaughter, this study argues that existing legal mechanisms inadequately address systemic corporate harm. The paper concludes that meaningful accountability requires a reconceptualization of mens rea, causation, and veil piercing in cases of pharmaceutical misconduct that foreseeably results in mass harm.

Introduction

The rise of corporate power in the pharmaceutical sector has significantly reshaped the relationship between law, public health, and criminal accountability. Pharmaceutical corporations possess immense influence over drug development, marketing, and distribution, often operating across jurisdictions with complex regulatory oversight. While this structure has facilitated innovation, it has also generated conditions under which corporate decision-making can produce catastrophic public health outcomes.

The opioid crisis represents one of the most severe examples of such systemic harm. Millions of deaths attributable to prescription opioid misuse have prompted extensive civil litigation and regulatory enforcement, yet criminal accountability at the corporate and executive levels remains limited. Similarly, incidents involving contaminated or adulterated pharmaceutical products have resulted in fatalities without corresponding criminal liability akin to homicide or manslaughter. These realities raise a fundamental question: whether existing doctrines of corporate criminal liability are capable of addressing mass harm caused by pharmaceutical enterprises.

This paper explores the concept of pharmaceutical corporate manslaughter by examining the intersection of corporate criminal liability, veil piercing, and public health harm. It interrogates whether the law should move beyond traditional models of individual culpability and negligence to recognize systemic corporate wrongdoing as a basis for criminal sanction.

Corporate Criminal Liability and the Pharmaceutical Industry

Foundations of Corporate Criminal Liability

Corporate criminal liability in common law jurisdictions is premised on the legal fiction that corporations are persons capable of bearing rights and obligations. Under U.S. law, corporations may be held criminally liable for acts committed by employees or agents acting within the scope of employment and, at least in part, for the benefit of the corporation. This doctrine of respondeat superior has enabled prosecutors to bring charges against corporate entities without identifying a single culpable individual.¹

However, this model remains deeply constrained. While corporations may be fined or subjected to compliance obligations, criminal law traditionally reserves its most severe sanctions, including incarceration and moral condemnation, for natural persons. As a result, corporate criminal liability often functions as a regulatory penalty rather than a mechanism of moral accountability.

Regulatory Enforcement in Pharmaceutical Law

Pharmaceutical misconduct is primarily addressed through specialized statutory regimes, most notably the Federal Food, Drug, and Cosmetic Act and the Controlled Substances Act.² These statutes impose strict regulatory requirements concerning manufacturing practices, labeling, marketing, and distribution. Violations frequently result in civil penalties or misdemeanor convictions, even where the consequences include serious bodily harm or death.

The regulatory orientation of these statutes reflects an assumption that pharmaceutical harms arise from technical noncompliance rather than criminal culpability. This assumption becomes problematic when corporate conduct demonstrates deliberate risk-taking, systematic deception, or reckless disregard for public safety.

The Opioid Crisis and Limits of Criminal Accountability

Civil Liability and Settlement Culture

The legal response to the opioid crisis has been dominated by civil litigation. States, municipalities, and private plaintiffs have secured multi-billion-dollar settlements against pharmaceutical manufacturers and distributors for deceptive marketing and failure to monitor suspicious orders.³ While these settlements acknowledge corporate wrongdoing, they do not impose criminal liability equivalent to the scale of harm inflicted.

Civil settlements, moreover, often permit corporations to deny liability and avoid judicial findings of culpability. From a criminal law perspective, this approach risks normalizing mass harm as a cost of doing business.

Criminal Prosecutions and Executive Immunity

Criminal prosecutions related to the opioid crisis have been narrowly tailored to misbranding, fraud, or racketeering offenses. The prosecution of Purdue Frederick Company Inc. and certain executives illustrates the reluctance of courts to extend criminal liability beyond statutory violations.⁴ Even where executives plead guilty, sanctions rarely reflect the gravity of the resulting public health catastrophe.

The Insys Therapeutics prosecutions represent a notable exception, as senior executives were convicted of racketeering conspiracy for orchestrating illegal marketing schemes.⁵ However, these cases remain anomalies rather than evidence of a broader shift toward criminal accountability for pharmaceutical executives.

Contaminated Pharmaceuticals and Criminal Responsibility

Incidents involving contaminated pharmaceutical products further expose the inadequacy of existing legal frameworks. In cases such as the Ranbaxy Laboratories scandal, corporations pled guilty to manufacturing and distributing adulterated drugs, yet criminal liability was limited to fines and compliance obligations.⁶

Internationally, courts have demonstrated greater willingness to impose criminal sanctions for pharmaceutical contamination. The Celobar incident in Brazil, in which contaminated contrast media caused patient deaths, resulted in prison sentences for corporate executives.⁷ These cases suggest that criminal accountability for pharmaceutical harm is not inherently incompatible with corporate activity, but rather reflects jurisdictional differences in legal philosophy.

Piercing the Corporate Veil in Criminal Law

Doctrine and Judicial Reluctance

The doctrine of piercing the corporate veil permits courts to disregard the separate legal personality of a corporation where it is used to perpetrate fraud or injustice. Courts, however, apply this doctrine sparingly, particularly in criminal cases. The seminal decision in Walkovszky v. Carlton illustrates judicial resistance to veil piercing absent clear evidence of abuse of the corporate form.⁸

In the pharmaceutical context, the complexity of corporate structures further insulates executives and shareholders from liability. Subsidiaries, contractual intermediaries, and diffuse decision-making processes obscure lines of responsibility, complicating efforts to attribute criminal intent.

Systemic Harm and Veil Piercing

Traditional veil piercing doctrine is ill-suited to address systemic harm arising from lawful corporate structures. Pharmaceutical misconduct often results not from isolated acts of fraud, but from institutional practices that prioritize profit over safety. In such cases, the insistence on individualized intent may function as a barrier to accountability rather than a safeguard of justice.

Corporate Manslaughter as a Conceptual Framework

Corporate manslaughter statutes, such as those enacted in the United Kingdom, recognize that organizational failure can result in death without requiring identification of a single culpable individual.⁹ While U.S. law lacks an equivalent framework, the concept offers a useful lens through which to evaluate pharmaceutical harm.

Applying a corporate manslaughter model to pharmaceutical misconduct would require rethinking causation and mens rea. Rather than focusing on individual intent, liability would attach where corporate policies or practices create a foreseeable risk of death that is realized on a large scale.

Conclusion

The opioid crisis and repeated incidents of contaminated pharmaceuticals reveal profound limitations in existing models of corporate criminal liability. While civil settlements and regulatory enforcement provide partial remedies, they fail to capture the moral gravity of mass harm caused by pharmaceutical enterprises. The reluctance to pierce the corporate veil or recognize corporate manslaughter reflects deeper tensions within criminal law regarding collective responsibility and systemic wrongdoing.

This paper argues that meaningful accountability requires doctrinal evolution. Criminal law must move beyond narrow conceptions of intent and causation to address organizational harm that is foreseeable, preventable, and profit-driven. Without such reform, pharmaceutical corporations will continue to operate within a legal framework that permits catastrophic harm without corresponding criminal consequence.

Citation(S):

1. N.Y. Cent. & Hudson River R.R. Co. v. United States, 212 U.S. 481 (1909).
2. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 301–399f; Controlled Substances Act, 21 U.S.C. §§ 801–971.
3. Massachusetts v. Purdue Pharma L.P., No. 1884CV01808 (Mass. Super. Ct. 2018).
4. United States v. Purdue Frederick Co., No. 1:07CR00029 (W.D. Va. 2007).
5. United States v. Kapoor, 447 F. Supp. 3d 347 (D. Mass. 2020).
6. United States v. Ranbaxy USA, Inc., No. 1:13-cr-00025 (D. Md. 2013).
7. Celobar Incident (Braz.), criminal convictions discussed in pharmaceutical contamination jurisprudence.
8. Walkovszky v. Carlton, 223 N.E.2d 6 (N.Y. 1966).
9. Corporate Manslaughter and Corporate Homicide Act 2007, c. 19 (U.K.).